Adrià Fernández-Torras
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adrià Fernández-Torras has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Miquel Duran-Frigola
Ersilia Open Source Initiative
3 shared publications - Patrick Aloy
Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Catalonia, Spain
3 shared publications - Martino Bertoni
Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain
2 shared publications - Alberto Pessia
University of Helsinki
1 shared publication - Andrea Califano
Department of Systems Biology, Columbia University, New York, USA
1 shared publication - Angel R. Nebreda
Institute for Research in Biomedicine (IRB Barcelona) The Barcelona Institute of Science and Technology Barcelona Spain
1 shared publication
Latest Publications
- Open Access
- 7 March 2023
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 22 (4) , 100527
Characterization of p38α Signaling Networks in Cancer Cells Using Quantitative Proteomics and Phosphoproteomics
- 7 March 2023
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 22 (4) , 100527
Open AccessCharacterization of p38α Signaling Networks in Cancer Cells Using Quantitative Proteomics and Phosphoproteomics
- Open Access
- 9 September 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-18
Integrating and formatting biomedical data as pre-calculated knowledge graph embeddings in the Bioteque
Biomedical data is accumulating at a fast pace and integrating it into a unified framework is a major challenge, so that multiple views of a given biological event can be considered simultaneously. Here we present the Bioteque, a resource of unprecedented size and scope that contains pre-calculated biomedical descriptors derived from a gigantic knowledge graph, displaying more than 450 thousand biological entities and 30 million relationships between them. The Bioteque integrates, harmonizes, and formats data collected from over 150 data sources, including 12 biological entities (e.g., genes, diseases, drugs) linked by 67 types of associations (e.g., ‘drug treats disease’, ‘gene interacts with gene’). We show how Bioteque descriptors facilitate the assessment of high-throughput protein-protein interactome data, the prediction of drug response and new repurposing opportunities, and demonstrate that they can be used off-the-shelf in downstream machine learning tasks without loss of performance with respect to using original data. The Bioteque thus offers a thoroughly processed, tractable, and highly optimized assembly of the biomedical knowledge available in the public domain.
- 9 September 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-18
Open AccessIntegrating and formatting biomedical data as pre-calculated knowledge graph embeddings in the Bioteque
Biomedical data is accumulating at a fast pace and integrating it into a unified framework is a major challenge, so that multiple views of a given biological event can be considered simultaneously. Here we present the Bioteque, a resource of unprecedented size and scope that contains pre-calculated biomedical descriptors derived from a gigantic knowledge graph, displaying more than 450 thousand biological entities and 30 million relationships between them. The Bioteque integrates, harmonizes, and formats data collected from over 150 data sources, including 12 biological entities (e.g., genes, diseases, drugs) linked by 67 types of associations (e.g., ‘drug treats disease’, ‘gene interacts with gene’). We show how Bioteque descriptors facilitate the assessment of high-throughput protein-protein interactome data, the prediction of drug response and new repurposing opportunities, and demonstrate that they can be used off-the-shelf in downstream machine learning tasks without loss of performance with respect to using original data. The Bioteque thus offers a thoroughly processed, tractable, and highly optimized assembly of the biomedical knowledge available in the public domain.
- 1 February 2022
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 66, 102090
Connecting chemistry and biology through molecular descriptors
- 1 February 2022
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 66, 102090
Connecting chemistry and biology through molecular descriptors
- Open Access
A Community Challenge for Pancancer Drug Mechanism of Action Inference from Perturbational Profile Data
The Columbia Cancer Target Discovery and Development (CTD 2 ) Center has developed PANACEA (PANcancer Analysis of Chemical Entity Activity), a collection of dose-response curves and perturbational profiles for 400 clinical oncology drugs in cell lines selected to optimally represent 19 cancer subtypes. This resource, developed to study tumor-specific drug mechanism of action, was instrumental in hosting a DREAM Challenge to assess computational models for de novo drug polypharmacology prediction. Dose-response and perturbational profiles for 32 kinase inhibitors were provided to 21 participating teams who were asked to predict high-affinity binding target among 255 possible protein kinases. Best performing methods leveraged both gene expression profile similarity analysis, and deep-learning methodologies trained on individual datasets. This study lays the foundation for future integrative analyses of pharmacogenomic data, reconciliation of polypharmacology effects in different tumor contexts, and insights into network-based assessment of context-specific drug mechanism of action.
Open AccessA Community Challenge for Pancancer Drug Mechanism of Action Inference from Perturbational Profile Data
The Columbia Cancer Target Discovery and Development (CTD 2 ) Center has developed PANACEA (PANcancer Analysis of Chemical Entity Activity), a collection of dose-response curves and perturbational profiles for 400 clinical oncology drugs in cell lines selected to optimally represent 19 cancer subtypes. This resource, developed to study tumor-specific drug mechanism of action, was instrumental in hosting a DREAM Challenge to assess computational models for de novo drug polypharmacology prediction. Dose-response and perturbational profiles for 32 kinase inhibitors were provided to 21 participating teams who were asked to predict high-affinity binding target among 255 possible protein kinases. Best performing methods leveraged both gene expression profile similarity analysis, and deep-learning methodologies trained on individual datasets. This study lays the foundation for future integrative analyses of pharmacogenomic data, reconciliation of polypharmacology effects in different tumor contexts, and insights into network-based assessment of context-specific drug mechanism of action.